French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that it will stop the phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are refractory to standard-of-care treatment.

This decision follows an interim review by an independent data monitoring committee, which concluded that the study is unlikely to demonstrate sufficient efficacy. No safety signals related to riliprubart were identified during the analysis.

Sanofi said it will work with investigators and study sites to wind down the trial and ensure appropriate transition of care for enrolled patients. The company will conduct a detailed analysis of the study data to support future research and advance scientific understanding of CIDP.

The continuation of other ongoing riliprubart studies, including the phase 3 VITALIZE trial in IVIg-treated CIDP patients, will be evaluated.

Sanofi stated that terminating the MOBILIZE study will not result in significant financial costs and does not affect its 2026 financial guidance.